Figure 3.
Treatment failure among patients with Crohn’s disease (CD) and ulcerative colitis (UC) treated with vedolizumab at post-induction, week 30 and week 52.
CMV, cytomegalovirus.
Treatment failure among patients with Crohn’s disease (CD) and ulcerative colitis (UC) treated with vedolizumab at post-induction, week 30 and week 52.
CMV, cytomegalovirus.